Biodesix (NASDAQ: BDSX)
Biodesix Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biodesix Company Info
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
News & Analysis
No articles found.
Valuation
Earnings Transcripts
Biodesix, Inc. (BDSX) Q2 2022 Earnings Call Transcript
BDSX earnings call for the period ending June 30, 2022.
Biodesix, Inc. (BDSX) Q1 2022 Earnings Call Transcript
BDSX earnings call for the period ending March 31, 2022.
Biodesix, Inc. (BDSX) Q4 2021 Earnings Call Transcript
BDSX earnings call for the period ending December 31, 2021.
Biodesix, Inc. (BDSX) Q3 2021 Earnings Call Transcript
BDSX earnings call for the period ending September 30, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.